This announcement is a separate document:
PharmaCyte Biotech | SC 13G: Statement of acquisition of beneficial ownership by individuals-Ayrton Capital LLC(9.9%),Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B(9.9%), etc.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.